The manufacture of IgM molecules for early clinical trials was done using hybridoma cells derived from rat or mouse myeloma cells or a heteromyeloma between human lymphoid cells and murine myeloma cells (see Table 3 in Section 6.1). This evidence concerns the gene CD40LG and plasma cell myeloma.